Harmony MindRhythm has announced that results from the pilot phase of its three-phase clinical study, EPISODE, have been published in Academic Emergency Medicine. While pilot EPISODE data have been presented in various academic society forums, this is the first official publication of results from the study, according to a press release from the company. The company claims that its family of EPISODE studies, assessing MindRhythm’s Harmony technology in the prehospital detection of ischaemic stroke, is the largest evaluation of a prehospital stroke device, with eight geographies, 17 hospitals a ..read more

Calvin Howard A study presented at the recent American Academy of Neurology (AAN) annual meeting (13–18 April, Denver, USA) has gone some way to elucidating how two factors—patient age, and connectivity of electrodes to the subiculum-retrosplenial cortex (SBC-RSC)—may impact the cognitive effects of deep brain stimulation (DBS) among Parkinson’s and Alzheimer’s patients. Delivering these findings on behalf of his co-investigators, Calvin Howard (Harvard Medical School, Boston, USA) outlined that he and his colleagues endeavoured to gain a better understanding of how patient age and electrode c ..read more

Route 92 Medical has today announced receipt of US Food and Drug Administration (FDA) 510(k) clearance for the FreeClimb 54 reperfusion system, comprised of the FreeClimb 54 aspiration catheter paired with a Tenzing 5 delivery catheter. This new system is part of a growing portfolio of neurovascular devices from Route 92, designed to work harmoniously as a complete endovascular thrombectomy solution to address a broad range of neurovascular interventions, according to a company press release. “Route 92 Medical works to provide innovative endovascular thrombectomy solutions to clinicians, helpi ..read more

Christian Taschner (L), Zsolt Kulcsár The European Society of Minimally Invasive Neurological Therapy (ESMINT) has issued a call for experts in neurointerventions to work with notified bodies over the certification process of medical devices within the European Union (EU). The society recently established a Medical Device Regulation (MDR) Task Force, chaired by ESMINT treasurer Christian Taschner (University Hospital Freiburg, Freiburg, Germany), with the aim of supporting the CE-certification process for neurointerventional medical devices by establishing a database of experts in this field ..read more

Viz.ai has announced a collaboration with Nico Corporation to improve the lives of patients with intracranial haemorrhages (ICHs), leveraging the former’s artificial intelligence (AI)-powered disease detection and intelligent care coordination products, and the latter’s modern, minimally invasive interventional technologies for neurosurgery. Through the power of Viz.ai’s technology, hospitals will be able to detect suspected disease earlier and receive accurate volume measurements of brain bleeds that are crucial for assessing the severity of ICH cases. In addition, Nico’s technology can provi ..read more

Insightec has announced the CE-mark approval and European launch of Exablate Prime, which the company describes as a “significant enhancement” to its Exablate Neuro platform—a magnetic resonance imaging (MRI)-guided neurosurgery system that uses focused ultrasound to treat medication-refractory essential tremor and Parkinson’s disease. Based on customer input and feedback, Exablate Prime is the culmination of more than 10 years of significant research and development designed to increase precision and efficiency, as per an Insightec press release. Like its predecessor, Exablate Prime enables i ..read more

Diogo Haussen (left), Pedro Martins A retrospective analysis including data from close to 3,000 stroke patients has concluded that early changes in mechanical thrombectomy strategies may be associated with higher reperfusion rates and therefore “should be contemplated” following failed attempts with first-line standalone contact-aspiration or stent-retriever approaches. The analysis in question—now published in the Journal of NeuroInterventional Surgery (JNIS) by Diogo Haussen, Pedro Martins (both Emory University School of Medicine, Atlanta, USA) and colleagues—was predicated on the fact that ..read more

Cerenovus, part of Johnson & Johnson MedTech, has today announced the launch of its Cereglide 71 aspiration catheter in Europe, an aspiration catheter equipped with TruCourse technology, indicated for the revascularisation of patients suffering from acute ischaemic stroke. The Cereglide 71 aspiration catheter is the latest innovation in a planned Cereglide family of catheters to join the Cerenovus stroke solutions portfolio. Cereglide 71 is optimised for effective, direct aspiration of blood clots and for the delivery of compatible stent retrievers, including the Embotrap III revascularisa ..read more

Cognito Therapeutics has announced treatment results from OVERTURE II—an open-label extension (OLE) study of Spectris, the company’s potential disease-modifying therapy for the treatment of Alzheimer’s disease. The results in question were presented at the 2024 American Academy of Neurology (AAN) annual meeting (13–18 April, Denver, USA). OVERTURE II involved a separate 12-month OLE protocol that followed the six-month OVERTURE I randomised controlled trial (RCT), and saw 83% of OVERTURE I study participants enrolled. OVERTURE I results were recently published in Frontiers in Neurology. O ..read more

After providing NeuroNews with an overview of the recent history of arteriovenous malformation (AVM) treatment in a previous video interview, Christophe Cognard (Toulouse University Hospital, Toulouse, France) summarises his own preferred approach to these cases, and takes a more detailed look at the future of interventional AVM care. The post Embolisation holds “very important, complementary” place in future of AVM treatment appeared first on NeuroNews International ..read more